Breast Cancer Diagnostic Market Report 2025 (Global Edition)

Global Breast Cancer Diagnostic Market Report 2025 Market Size Split by Test Type (Imaging (Mammography, Analog Mammography, Digital Mammography, Breast Ultrasound System, MRI Scan, PET/CT Scan), Biop...

Breast Cancer Diagnostic Market Report Description

We have various report editions of Breast Cancer Diagnostic Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Competitive Landscape: Breast Cancer Diagnostics market

To strengthen their product portfolio, the major market players use organic and inorganic expansion tactics. To stay competitive in the global breast cancer diagnostics market, these companies have used methods such as geographic growth, collaborations, acquisitions, investment in research and development, and manufacturing of novel breast cancer diagnostic tools in the market.

•    In May 2023, Thermo Fisher Scientific and Pfizer entered into a strategic partnership to enhance the global availability of NGS-based testing for cancer patients. This partnership aims to expand localized access to advanced genomic diagnostics, empowering international markets with improved capabilities for precision cancer care.
(Source;https://www.pfizer.com/news/press-release/press-release-detail/thermo-fisher-scientific-pfizer-partner-expand-localized)

•    In June 2023, Paige AI, Inc. launched its AI-powered “Paige Breast Suite”, which contains a set of products that can help pathologists with a breast cancer diagnosis. 
(Source:https://paige.ai/blog/paiges-research-propels-ai-utilization-in-pathology/)

•    In February 2023, HALO Breast Care Center launched the new HALO PathWay, a breast cancer screening approach that can provide diagnostic processes such as genetic testing and advanced imaging under one roof.
(Source:https://www.halodx.com/blog/halo-breast-care-center-launches-new-halo-pathway-for-early-detection-of-breast-cancer/)

Top Companies Market Share in Breast Cancer Diagnostic Industry: (In no particular order of Rank)

• Genomic Health
• NanoString Technologies Inc.
• Paragon Biosciences LLC
• Devicor Medical Products Inc.
• AstraZeneca
• Quest Diagnostics Incorporated
• Koninklijke Philips N.V.
• Siemens AG
• Biocept Inc.
• Epigenomics Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Market in 2024, and Which Region is Expanding at the Fastest CAGR?

The largest global market shareholder, North America is expected to expand at a compound annual growth rate (CAGR) of XX% throughout the course of the projection period. North America dominated the market with a revenue share of 45.8% in terms of revenue in 2022. The growth can be attributed to the increasing prevalence of breast cancer and rising government initiatives to increase the screening & diagnostic rate. For instance, according to the American Cancer Society, there were approximately 49,290 breast cancer-related fatalities in the U.S. in 2021, with an expected 281,550 new cases of breast cancer being diagnosed. The U.S. held the largest market share of the market in North America. The growth can be attributed to the increasing prevalence of breast cancer and rising government initiatives aimed at enhancing screening & diagnostic rates in the country. There is a growing demand for technologically advanced products that offer improved accuracy, speed, and cost-effectiveness, which is expected to drive market growth over the forecast period.

Asia Pacific market is expected to grow at a lucrative rate owing to various factors, such as increasing healthcare reforms, rising incidence of breast cancer, significant R&D investments in breast cancer therapies, and advancements in breast imaging technologies. Breast cancer is the most commonly diagnosed cancer in most Asian countries, with incidence rates rising at a faster rate compared to Western countries due to lifestyle and dietary changes. The CDC highlights breast cancer as a prevalent cancer among women, regardless of ethnicity or race. The rising prevalence of breast cancer, coupled with the development of healthcare infrastructure in Asia Pacific, is expected to drive overall market growth.

The current report Scope analyzes Breast Cancer Diagnostic Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Breast Cancer Diagnostic Market Analysis

How is Types Segment Performing in the Breast Cancer Diagnostics Market?

Based on type, In 2022, the imaging section held a 52.74% revenue share, making it the dominant segment overall. The market is divided into categories based on kind, including imaging, biopsy, genetic testing, blood testing, and others. The market for breast cancer diagnostics expanded significantly in 2022 as a result of the extensive use of imaging methods such as MRI, ultrasound, and mammography. While new technologies like MBI, CT, 3D breast tomosynthesis, and PET offer significant potential for revolutionizing breast imaging capabilities, these modalities have become the key instruments for the diagnosis of breast cancer.

In October 2022, the Contrast-Enhanced Mammography Imaging Screening Trial (CMIST) was initiated by the American College of Radiology (ACR) in association with GE Healthcare and the Breast Cancer Research Foundation. The purpose of this trial is to assess how well contrast-enhanced mammography works as a breast cancer screening method.

Over the course of the projection period, the blood test segment is expected to develop at the quickest growth rate—a CAGR of 9.9%—thanks to intensive research studies carried out by prominent companies and research organizations. The rising number of blood tests is partly due to the great efficacy of liquid biopsy tests. Using the Syantra DX Liquid Biopsy Platform, which provides a blood-based approach for breast cancer screening, Syantra was able to obtain CE Mark clearance for their breast cancer test in April 2023. Reaching this milestone represents a major advancement in breast cancer screening diagnostics.

•    Imaging (Mammography, Analog Mammography, Digital Mammography, Breast Ultrasound System, MRI Scan, PET/CT Scan)
•    Biopsy
•    Genomic Tests
•    Blood Tests
•    Others

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Breast Cancer Diagnostic Industry. Request a Free Sample PDF!

Which Application Segment holds the largest revenue share of the Breast Cancer Diagnostics Market?

Based on application, The market is divided into four segments based on application: screening, diagnostic & predictive, prognostic, and research. In 2022, the diagnostic and predictive sector held a 48.4% revenue share, dominating the overall market. Breast cancer is diagnosed using a series of procedures, including biopsies, MRIs, CT scans, and PET scans, which determine the tumor's features and confirm the cancer's presence. These tests are vital for determining the best course of treatment and obtaining critical data regarding the illness. The market for breast cancer diagnostics is becoming more and more competitive, and predictive diagnosis is receiving more attention.

Over the course of the projection period, the prognostic segment is anticipated to increase at a CAGR of 8.4%. Survival rates have increased dramatically as a result of prognostic testing' growing significance in matching patients with the right treatments. In this process, companion diagnostics are essential. Examples of these diagnostics are PD-L1 IHC 22C3 pharmDx by Dako North America, Inc.; BRACAnalysis CDx by Myriad Genetic Laboratories, Inc.; and Foundation One CDx by Foundation Medicine, Inc. At the American Society of Clinical Oncology (ASCO) 2023, Exact Sciences presented innovative long-term patient outcomes in breast cancer recurrence testing and multi-cancer early detection. The SEER program research confirms the ongoing belief in the Oncotype DX Breast Recurrence Score 3's predictive significance. 

•    Screening
•    Diagnostic and Predictive
•    Prognostic
•    Research

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Breast Cancer Diagnostic Product Type Segment Analysis

On the basis of Product, The market is divided into platform-based products and instruments-based products based on the kind of product. In 2022, the instrument-based products sector held a 71.8% revenue share, making it the dominant segment in the total market. It is divided further into imaging and biopsy. The diagnosis of breast cancer is mostly dependent on commonly used methods and tools. Numerous organizations, such as the National Breast Cancer Foundation, are actively launching campaigns to increase public awareness of breast cancer, encourage early identification, and inform individuals about available treatment options. The gold standard for population-based screening of patients for breast cancer is imaging.

Over the course of the projection period, the platform-based products segment is expected to increase at a CAGR of 9.3%. Microarrays, PCR, Next-generation Sequencing (NGS), and other products are categorized under platform-based products. Because this segment is widely used in laboratories and has low false-positive rates, it is expected to grow at a compound annual growth rate (CAGR) of 9.3%. Furthermore, these tests help patients receive a medicine that is more appropriate for their genetic make-up and type of illness.

• Platform-based Products
• Instrument-based Products

Breast Cancer Diagnostic End-Users Segment Analysis

Based on the End-users, the market is divided into hospitals and clinics, diagnostic centers and medical laboratories, and other segments based on the end-use. With a revenue share of 50.6% in 2022, the hospitals & clinics sector led the overall market, largely because of the rising number of hospitalizations and rising incidence of breast cancer. After the initial screening tests, these medical facilities are essential for performing biopsy procedures. They also use modern imaging technologies like PET, CT, and MRI for efficient disease monitoring and therapy evaluation.

With a CAGR of 8.1%, the medical labs & diagnostics centers category is predicted to develop at the quickest rate during the forecast period. Growth in the market is anticipated to be aided by an increase in the number of government initiatives to offer different services, such as paying for diagnostic testing. A lot of medical facilities are collaborating with labs to incorporate various tests, such MRIs, ultrasounds, and mammograms.

• Hospitals & Clinics
• Diagnostic Centers and Medical Laboratories
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion